The theme of the 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima) is “Harmonization of innovative drug development and sustainable health care from Hiroshima to the world“.
Symposium
Recent progress in partnerships for NTD drug discovery in 2021
This symposium aims to report on the achievements and future development of the “NTD Drug Discovery Booster” that has been implemented with GHIT support since 2015, and the game-changing partnerships of industry-academia-government for new drug discovery and are happy to discuss the expected role of Japan in future drug discovery for NTDs.
Organizer: Yamada Haruki, Professor emeritus of Kitasato University, Japan and Chair of the DNDi Japan Board of Directors, and Nozaki Tomoyoshi, University of Tokyo
Date: Sunday, 28 March 2021
Time: 15:45-17:45
| NTD Drug Discovery Booster, achievements, and next steps Kuzuki T, Benjamin P, Mowbray C (DNDi) |
| Corporate efforts to research and develop therapeutic agents for infectious diseases that threaten human Yoshida R, Kaki R, Yoshida O, Shishido T, Kato T, Yamano Y (Shionogi & Co., Ltd.) |
| Partnership activity for neglected tropical diseases Akao Y, Ochida A, Muranishi H, Nomura I, Ichikawa T (Takeda Pharmaceutical Company) |
| A strategic partnership for the medicine creation and provision against neglected tropical diseases Katsura Hata (Eisai) |
| Nucleic acid-based Immuno-prophylaxis and -therapies against tropical diseases Ken Ishii (Institute of Medical Science University of Tokyo and Institute of Biomedical Innovation, Health and Nutrition) |
| Introduction of Astellas’ “Access to Health” initiatives for neglected tropical diseases (NTDs) ~R&D of NTD medicines~ Fumiya Domoto (Astellas) |
